InvestorsHub Logo
Followers 39
Posts 7992
Boards Moderated 2
Alias Born 11/14/2019

Re: None

Friday, 09/23/2022 7:06:01 PM

Friday, September 23, 2022 7:06:01 PM

Post# of 20347
I have an idea. Anyone up on the clinical side of things?

“An inhibitor of 3CL protease (3CLpro), Tollovir is an anti-cytokine treatment candidate for the nidovirus subgroup of coronaviruses such as SARS-CoV-2, SARS-CoV-1, MERS and 229E.”

"The dried root of Lithospermum erythrorhizon is indigenous to northeast China and has potent biological activities, including anti-inflammatory, antibacterial, antiangiogenic, and antitumour qualities [261]. Shikonin, a naphthoquinone, is extracted from the root of Lithospermum erythrorhizon and stimulates the activity of caspases, poly-(ADP-ribosyl) polymerase (PARP) and reactive oxygen species (ROS), triggering programmed cell death in cancer cell lines [262]. These characteristics prompted investigation of shikonin as a novel scar remediation therapy. These studies found that shikonin inhibits cell proliferation and collagen production in hypertrophic scar-derived human skin fibroblasts [263]. Arnebin-1, a related naphthoquinone extracted from Lithospermum erythrorhizon, has been reported to synergise with VEGF, resulting in significantly improved wound healing in a rat diabetic model..."

Todos , I'm sure, have lots of clinical data out besides what's found on their site.

Anti-cytokine alone is huge.

I think their product looks impressive , but I personally haven't tried it yet. But I will.